Eurofins Scientific


Top-line growth improves in Q3

08/11/19 -"Eurofins reported reassuring top-line growth in Q3 FY19 – the performance was spread across all geographies except for the UK. The growth is likely to be sustained in Q4 FY19, in our opinion. ..."

Pages
47
Language
English
Published on
08/11/19
You may also be interested by these reports :
12/08/26
Bilfinger’s Q2 revenue grew by 7% to €1.45bn and EBITA by 4% to €77m, both slightly ahead of expectations, but the underlying picture weakened. The ...

06/08/26
Q2 2026 confirmed solid revenue growth, driven by Adecco GBU’s strong performance across the Americas, Asia Pacific and most EMEA regions. While ...

05/08/26
When we last teased on Rentokil (RTO) (REDUCE; UK) ~16 months ago, our optimism stemmed from on-track Terminix integration. The stock price also ...

03/08/26
We have only fine-tuned our estimates, with no material impact on valuation. That said, we have also reduced the discount to peers in the comparable ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO